Market Overview

Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know


JPMorgan’s Anupam Rama believes data from the two phase 3 trials of fostamatinib would be positive and that Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s stock could see 90-150 percent upside if that was the case.

The analyst upgraded the rating on the company from Neutral to Overweight, with a $5 price target.

Rama also pointed out that in the event that the data was negative, the worst-case scenario would a 55 percent downside to the stock, from its current levels.

Data Expectations

Top-line Phase 3 data for fostamatinib in idiopathic thrombocytopenic purpura (ITP) is expected in mid-2016, with a potential NDA filing in early-2017. The analyst estimates worldwide peak sales for the drug at $360 million.

Rama mentioned that physician feedback for the earlier Phase 2 data had been positive, highlighting robust early proof of concept.

“We view ~20 percent improvement in sustained response over placebo as the beatable / clinically meaningful phase 3 activity benchmark,” Rama stated, while adding, “Based on physician commentary, we do not have any over-arching safety concerns.”

The analyst believes that there is high probability of success for the ongoing Phase 3 trials, and noted that topline fostamatinib data, expected in mid-2016, could be a “transformative catalyst” for Rigel Pharmaceuticals.

Latest Ratings for RIGL

Sep 2019AssumesOverweight
Aug 2018Initiates Coverage OnBuy
May 2018MaintainsOutperformOutperform

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Anupam Rama J.P. MorganAnalyst Color Long Ideas Upgrades Analyst Ratings Trading Ideas


Related Articles (RIGL)

View Comments and Join the Discussion!

Top Performing Industries For April 22, 2016

NGL Energy Soars As Oaktree Announces $200 Million Investment